FLLL12
FLLL12 (GO-Y026) is a curcumin analog anticancer agent. FLLL12 inhibits the phosphorylation of AKT, Bcl-2, Bid, EGFR, mTOR, FOXO1a, FOXO3a, STAT3, HER2/neu, as well as pancreatic AKT/STAT3; upregulates the expression of Bim and DR5; and activates PTPs. FLLL12 regulates downstream pathways, induces mitochondria-mediated and DR5-dependent extrinsic apoptosis, inhibits cancer cell viability, proliferation, anchorage-independent growth and migration, and exerts a synergistic effect with Doxorubicin (HY-15142A). FLLL12 can be used in research related to head and neck squamous cell carcinoma, breast cancer, prostate cancer, pancreatic cancer, lung cancer, colon cancer and colorectal cancer.
For research use only. We do not sell to patients.
- CAS No.: 917813-60-6
- Formula: C21H22O7
- Molecular Weight:386.40
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All EGFR Isoforms
More
Biological Activity
Description
|
STAT3 |
Bcl-2 |
Bim |
mTOR |
FOXO1a |
FOXO3a |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | GI50 |
0.8 μM
Compound: GO-Y026
|
Growth inhibition of human HCT116 cells after 48 hrs by MTS assay
Growth inhibition of human HCT116 cells after 48 hrs by MTS assay
|
[PMID: 20060305] |
| HT-29 | IC50 |
2.24 μM
Compound: C9
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 22551677] |
| LNCaP | IC50 |
2.5 μM
Compound: 19
|
Antiproliferative activity against human LNCAP cells after 72 hrs by MTT assay
Antiproliferative activity against human LNCAP cells after 72 hrs by MTT assay
|
[PMID: 19249204] |
| MCF7 | IC50 |
1.7 μM
Compound: 19
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 19249204] |
| MDA-MB-231 | IC50 |
2.7 μM
Compound: 19
|
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay
|
[PMID: 19249204] |
| PANC-1 | IC50 |
2.23 μM
Compound: C9
|
Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay
Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay
|
[PMID: 22551677] |
| PC-3 | IC50 |
3.6 μM
Compound: 19
|
Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 19249204] |
| PC-3 | IC50 |
3.41 μM
Compound: C9
|
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 22551677] |
In Vitro
FLLL12 (GO-Y026) potently inhibits the growth of human colon cancer HCT-116 cells after 48 h exposure, with a GI50 value of 0.8 μM[1].
FLLL12 (0.5-5 μM; 72 h) potently inhibits the viability of MDA-MB-468, MDA-MB-231, SK-BR-3, BT-474, MDA-MB-453, MCF-7, PC-3 and DU145 cancer cells, with IC50 values of 0.3, 2.7, 3.8, 1.8, 1.3, 1.7, 3.6 and 3 μM, respectively, while showing extremely low toxicity against the normal human lung fibroblast cell line WI-38[2].
FLLL12 (1-10 μM; 24 h) significantly inhibits the DNA-binding activity of STAT3 in MDA-MB-231, SK-BR-3 and DU145 cancer cells, and suppresses STAT3-dependent transcriptional activity in stably transfected MDA-MB-231 cells in a dose-dependent manner[2].
FLLL12 (1-5 μM; 2 weeks) inhibits anchorage-independent colony formation in MDA-MB-231 and SK-BR-3 breast cancer cells. At the concentration of 5 μM, it reduces the number of colonies in MDA-MB-231 cells by approximately 95% and almost completely suppresses colony formation in SK-BR-3 cells[2].
FLLL12 (5-10 μM; 4 h) inhibits the migration of MDA-MB-231 breast cancer cells in a dose-dependent manner, reducing the wound healing rate to approximately 65% and 28% of that in the control group at concentrations of 5 μM and 10 μM, respectively, with no significant cytotoxicity[2].
FLLL12 (5 μM; 72 h) acts synergistically with Doxorubicin (HY-15142A) (100-400 nM) to inhibit the viability of MDA-MB-231 breast cancer cells, with a combination index value <1[2].
FLLL12 (1.0-20 μM; 72 h) potently inhibits the viability of human pancreatic cancer cells including PANC-1, BXPC-3, MIA-PACA-2, ASPC-1 and HPAC, with IC50 values ranging from 0.91 to 3.43 μmol/l; this compound exhibits stronger activity in HPDE cells (IC50 0.26 μmol/l), while exerting minimal effects on normal human bladder cells (IC50 886.76 μmol/l)[3].
FLLL12 (72 h) potently inhibits the growth of human lung cancer premalignant and malignant cell lines, with IC50 values ranging from 0.63 to 1.87 μM[5].
FLLL12 (72 h) potently inhibits the viability of HCT116, HT-29 and SW480 human colorectal cancer cells, with IC50 values of 2.49 μM, 3.35 μM and 1.17 μM, respectively; meanwhile, this compound exhibits low toxicity to WI-38 human normal lung fibroblasts (IC50 > 1000 μM)[4].
FLLL12 (72 h) potently inhibits the growth of the premalignant cell line MSK-Leuk1 and malignant cell lines of head and neck squamous cell carcinoma (SCCHN) (Tu212, Tu177, MDA886LN, Tu686, SqCCY1, JHU022, PCI-13, UM-22B), with IC50 values ranging from 0.35 to 1.55 μmol/L[6].
FLLL12 (1-3 μM; 24-48 h) induces apoptosis in head and neck squamous cell carcinoma (SCCHN) cell lines (Tu686, MDA886LN, Tu212, UM-22B, MSK-Leuk1) in a dose- and time-dependent manner[6].
FLLL12 (1-3 μM; 24 h) inhibits the phosphorylation of mTOR, S6, 4EBP1, FOXO1a and FOXO3a in Tu212, Tu686 and MSK-Leuk1 head and neck squamous cell carcinoma cells[6].
FLLL12 (1-2 μM) induces mitochondria-mediated endogenous apoptosis in Tu212 head and neck squamous cell carcinoma cells by promoting the release of cytochrome C from mitochondria into the cytoplasm[6].
FLLL12 (1-3 μM; 24 h) regulates the expression of Bcl-2 family proteins in Tu212 and Tu686 head and neck squamous cell carcinoma cells; it decreases the levels of Bcl-2 and full-length Bid, and increases the level of Bim, thereby promoting cell apoptosis[6].
FLLL12 (2-3 μM; 48 h) induces apoptosis in Tu686 head and neck squamous cell carcinoma (SCCHN) cells, while overexpression of Bcl-2 significantly attenuates this effect, confirming that Bcl-2 is a key mediator of the pro-apoptotic effect of FLLL12[6].
FLLL12 (1-3 μM) upregulates the expression of Bcl-2 mRNA in Tu212 and Tu686 head and neck squamous cell carcinoma cells, indicating that its inhibitory effect on Bcl-2 protein occurs at the translational level[6].
FLLL12 (1-3 μM) inhibits the expression of EGFR and AKT mRNA in Tu212 and Tu686 head and neck squamous cell carcinoma (SCCHN) cells, indicating that its inhibitory effect on EGFR and AKT proteins occurs at the transcriptional level[6].
FLLL12 (3 μM; 48 h) induces apoptosis in Tu686 head and neck squamous cell carcinoma (SCCHN) cells, and knockdown of Bim significantly attenuates this effect, confirming that Bim is a key mediator of the pro-apoptotic action of FLLL12[6].
FLLL12 (3 μM; 48 h) induces apoptosis in Tu686 head and neck squamous cell carcinoma (SCCHN) cells, and knockdown of Bid significantly attenuates this effect, confirming that Bid is a key mediator of the apoptotic effect of FLLL12[6].
FLLL12 (5-10 μM; 24 h) downregulates the expression of HER2/neu in BT-474, SK-BR-3 and MDA-MB-453 breast cancer cells, and inhibits the phosphorylation of AKT Ser473 in MDA-MB-453 breast cancer cells and PC-3 prostate cancer cells. Meanwhile, FLLL12 increases the levels of cleaved PARP in BT-474, SK-BR-3, MDA-MB-453 and PC-3 cells, and elevates the levels of cleaved caspase-3 in SK-BR-3, MDA-MB-453 and PC-3 cells, indicating that it induces cell apoptosis[2].
FLLL12 (10 μM; 24 h) inhibits the phosphorylation of STAT3 (Tyr705) in MDA-MB-231, SK-BR-3 and DU145 cancer cells, induces apoptosis in these cancer cells, and does not trigger apoptosis in normal HMEC or WI-38 cells[2].
FLLL12 (5-10 μM; 24-48 h) inhibits the phosphorylation of STAT3 and induces apoptosis in PANC-1, BXPC-3 and HPAC human pancreatic cancer cells via cleaved caspase-3 or cleaved PARP. After 24-48 h of treatment, 10 μmol/l of this agent also inhibits the phosphorylation of AKT in BXPC-3 cells[3].
FLLL12 (5-10 μM; 24-48 h) inhibits STAT3 phosphorylation and induces apoptosis in PANC-1, HPAC and MIA-PACA-2 human pancreatic cancer cells[3].
FLLL12 (3-5 μM; 48 h) induces approximately 80% apoptosis in premalignant and malignant human lung cancer cell lines in a dose- and time-dependent manner[5].
FLLL12 induces apoptosis in human lung cancer cell lines H1299, H292 and A549, which is evidenced by the cleavage of caspase-3 and PARP[5].
FLLL12 (24 h) induces apoptosis in human lung cancer cell lines A549, H1299 and H292 via a pathway dependent on death receptor 5 (DR5) and requiring the involvement of caspase-8 and Bid, in which DR5 and caspase-8 play more critical roles than Bid[5].
FLLL12 (incubated for 24 h) activates caspase-8 and cleaves Bid into tBid in human lung cancer cell lines A549 and H1299, thereby inducing apoptosis[5].
FLLL12 (24 h) induces the expression of DR5 and subsequent apoptosis in the human lung cancer cell line A549, and this process depends on the activation of protein tyrosine phosphatases (PTPs); because inhibition of PTPs (but not alkaline phosphatase) blocks these effects[5].
FLLL12 induces apoptosis in human lung cancer cell lines H292 and H1299 in a p53- and p73-independent manner[5].
FLLL12 (2.5-5 μM; 24 h) induces apoptosis in human colorectal cancer cells HCT116, HT-29 and SW480 (as confirmed by cleaved PARP and cleaved caspase-3), but fails to induce the production of cleaved PARP in normal human lung fibroblasts WI-38 and mammary epithelial cells MCF-10A[4].
FLLL12 (1-3 μM; 24-48 h) inhibits the phosphorylation and total protein levels of EGFR and AKT in Tu212, Tu686 and MSK-Leuk1 head and neck squamous cell carcinoma (SCCHN) cells, with the inhibition of phosphorylated AKT occurring earlier than the downregulation of total AKT[6].
FLLL12 (1-3 μM; 48 h) induces apoptosis in Tu686 SCCHN cells, and overexpression of constitutively active AKT significantly attenuates this effect, confirming that AKT inhibition is a key mediator of the pro-apoptotic effect of FLLL12[6].
Treatment of immortalized human pancreatic ductal epithelial (HPDE) cells with FLLL12 (5 μM; 24-48 h) for 24-48 h does not induce apoptosis (detected via activated caspase-3)[3].
FLLL12 (24 h; 2 h) post-transcriptionally (possibly at the translational level) regulates the expression of DR5 in human lung cancer cell lines A549 and H1299, with no effect on DR5 mRNA levels[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Tu686, MDA886LN, Tu212, UM-22B, MSK-Leuk1
-
Concentration:1-3 μM (24 h incubation); 1-3 μM (48 h incubation); 1-3 μM (24 h incubation in MSK-Leuk1 cells)
-
Incubation Time:24 h; 48 h
-
Result:Induced apoptosis in a dose- and time-dependent manner across all tested cell lines.
Induced approximately 80% apoptosis in most cell lines after treatment with 1 to 3 μmol/L for 48 hours.
Induced over 80% apoptosis in MSK-Leuk1 cells after 24 hours of treatment with 3 μmol/L.
-
Cell Line:Tu212, Tu686, MSK-Leuk1
-
Concentration:1-1.5 μM (Tu212); 2-3 μM (Tu686); 1-3 μM (MSK-Leuk1)
-
Incubation Time:24 h
-
Result:Markedly induced cleavage of PARP (a marker of apoptosis) in all three tested cell lines.
Strongly inhibited phosphorylation of mTOR, S6, and 4EBP1 (components of the mTOR-mediated protein translational pathway).
Inhibited phosphorylation of FOXO1a and FOXO3a at multiple sites in all three tested cell lines.
-
Cell Line:Tu212, Tu686
-
Concentration:1-1.5 μM (Tu212); 2-3 μM (Tu686)
-
Incubation Time:24 h
-
Result:Decreased protein expression of antiapoptotic Bcl-2 and full-length proapoptotic Bid.
Increased protein expression of proapoptotic Bim.
Left expression of Bcl-xL and Mcl-1 mostly unchanged.
-
Cell Line:Tu686
-
Concentration:2, 3 μM
-
Incubation Time:48 h
-
Result:Overexpression of Bcl-2 significantly protected Tu686 cells from FLLL12-induced apoptosis, with apoptosis rates reduced by approximately 50% compared to control cells at both tested concentrations.
-
Cell Line:Tu686
-
Concentration:3 μM
-
Incubation Time:48 h
-
Result:Ablation of Bim expression significantly protected Tu686 cells from FLLL12-induced apoptosis, reducing apoptosis rates from approximately 45% in control siRNA-transfected cells to approximately 20% in Bim siRNA-transfected cells.\n
Ablation of Bid expression significantly protected Tu686 cells from FLLL12-induced apoptosis, reducing apoptosis rates from approximately 55% in control siRNA-transfected cells to approximately 30% in Bid siRNA-transfected cells.
-
Cell Line:Tu212, Tu686, MSK-Leuk1
-
Concentration:1-1.5 μM (Tu212); 2, 3 μM (Tu686); 1-3 μM (MSK-Leuk1)
-
Incubation Time:24 h; 48 h
-
Result:Potently inhibited phosphorylation of EGFR and AKT, and also reduced total EGFR and AKT protein levels in all three tested cell lines, with greater potency than curcumin.
Inhibition of phosphorylated AKT preceded inhibition of total AKT at 12 hours of treatment.
-
Cell Line:Tu686
-
Concentration:1-3 μM
-
Incubation Time:48 h
-
Result:Overexpression of CA-AKT significantly protected Tu686 cells from FLLL12-induced apoptosis, reducing apoptosis rates by approximately 40% to 50% compared to control cells at tested concentrations.
Overexpression of CA-AKT inhibited FLLL12-induced PARP cleavage, caspase-3 activation, and Bim upregulation, and reduced FLLL12-mediated inhibition of Bcl-2.
-
Cell Line:BT-474, SK-BR-3, MDA-MB-453, PC-3
-
Concentration:5-10 μM
-
Incubation Time:24 h
-
Result:Downregulated HER2/neu protein expression in BT-474, SK-BR-3, and MDA-MB-453 breast cancer cells.
Inhibited AKT phosphorylation (Ser473) in MDA-MB-453 breast cancer cells and PC-3 prostate cancer cells, and decreased total AKT expression in MDA-MB-453 cells.
Induced apoptosis in all tested cancer cell lines, as evidenced by increased levels of cleaved PARP and cleaved caspase-3.
-
Cell Line:MDA-MB-231, SK-BR-3, DU145, HMEC, WI-38
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Inhibited STAT3 phosphorylation (Tyr705) in MDA-MB-231, SK-BR-3, and DU145 cancer cells, without affecting ERK1/2 phosphorylation.
Induced apoptosis in these cancer cells, as shown by increased cleaved PARP and cleaved caspase-3 levels.
Did not induce cleaved PARP or cleaved caspase-3 in normal HMEC or WI-38 cells.
-
Cell Line:MDA-MB-231
-
Concentration:5-10 μM
-
Incubation Time:4 h
-
Result:Impaired MDA-MB-231 cell migration.
At 5 μM, reduced wound healing to ~65% of control levels; at 10 μM, further reduced to ~28% of control levels.
Inhibitory effect was not due to cytotoxicity, as cell viability remained high after treatment.
-
Cell Line:MDA-MB-231
-
Concentration:5000 nM (FLLL12); 100-400 nM (doxorubicin)
-
Incubation Time:72 h
-
Result:All tested combinations of doxorubicin and FLLL12 resulted in CI values <1, indicating synergistic growth inhibition of MDA-MB-231 cells.
-
Cell Line:human pancreatic cancer cell lines (PANC-1, BXPC-3, HPAC)
-
Concentration:5 μM, 10 μmol/l
-
Incubation Time:24-48 h
-
Result:Inhibited STAT3 phosphorylation (Tyr705) and increased levels of cleaved caspase-3 in PANC-1 cells.
Inhibited STAT3 phosphorylation, induced significant levels of cleaved PARP in BXPC-3 cells; 10 μmol/l inhibited AKT phosphorylation (Ser473) in BXPC-3 cells.
Inhibited STAT3 phosphorylation and increased levels of cleaved caspase-3 in HPAC cells.
-
Cell Line:immortalized human pancreatic duct epithelial (HPDE) cells
-
Concentration:5 μM
-
Incubation Time:24-48 h
-
Result:Did not induce increased levels of cleaved caspase-3.
-
Cell Line:human pancreatic cancer cell lines (PANC-1, HPAC, MIA-PACA-2)
-
Concentration:5 μM, 10 μM
-
Incubation Time:24-48 h
-
Result:Inhibited STAT3 phosphorylation and induced cleaved caspase-3 at levels similar to the curcumin analogue GO-Y030 in PANC-1 cells.
Inhibited STAT3 phosphorylation and induced cleaved caspase-3 in HPAC cells.
Induced cleaved PARP and cleaved caspase-3 at levels similar to GO-Y030 in MIA-PACA-2 cells.
-
Cell Line:premalignant and malignant human lung cancer cell lines
-
Concentration:3-5 μM
-
Incubation Time:48 h
-
Result:Induced apoptosis in a dose- and time-dependent manner.
Induced ~80% apoptosis in lung cancer cell lines, a level of apoptosis that required 15-30 μM curcumin to achieve.
-
Cell Line:HCT116, HT-29, SW480 human colorectal cancer cells, WI-38 normal human lung fibroblasts, MCF-10A immortalized human mammary epithelial cells
-
Concentration:2.5 μM, 5 μM
-
Incubation Time:24 h
-
Result:Induced increased levels of cleaved PARP and cleaved caspase-3 in HCT116 cells at 2.5 μM and 5 μM.
Induced increased levels of cleaved PARP and slightly increased levels of cleaved caspase-3 in HT-29 cells at 5 μM.
Induced increased levels of cleaved PARP and cleaved caspase-3 in SW480 cells at 5 μM.
Did not induce cleaved PARP in WI-38 cells or MCF-10A cells.
Parmacokinetics
| Species | Dose | Route | Tmax | Cmax | T1/2 | AUClast | Clearance (CL) |
|---|---|---|---|---|---|---|---|
| Mice[6] | 200 mg/kg | p.o. | 0.5 h | 241.5 ng/mL | 4.8 h | 418.1 ng·h/mL | 449.2 L/h/kg |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:athymic nu/nu (female, 4 to 6 weeks old, ~20 g, subcutaneous xenograft of 4×106 Tu686 cells)[6]
-
Dosage:50 mg/kg
-
Administration:i.p.; once daily, 5 days per week; 17 days
-
Result:Reduced average tumor volume to ~600 mm3 at day 17, compared with ~1200 mm3 in vehicle and curcumin-treated groups (P < 0.05).
Showed no significant changes in body weight.
Exhibited no notable toxicities in histopathological analysis of major organs.
Chemical Information
-
CAS No. 917813-60-6
-
Molecular Weight 386.40
-
Formula C21H22O7
-
SMILES
COC(C=C1/C=C/C(/C=C/C2=CC(OC)=C(C(OC)=C2)O)=O)=C(C(OC)=C1)O
-
Synonyms
GO-Y026
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Soft Agar Colony Formation Assay
Soft agar colony formation assay measures anchorage-independent growth, in which transformed or tumorigenic cells proliferate as colonies in a semisolid agar matrix while many non-transformed adherent cells fail to proliferate without attachment; classic studies showed that growth in semisolid medium correlates with tumorigenicity in nude mice, and later protocol papers describe the method as a stringent in vitro assay for malignant transformation. The readout is the number, size, morphology, or signal intensity of colonies formed within agar after incubation; published formats include manual colony counting after staining, 96-well or 384-well quantitative formats, DNA-binding dye detection, MTT/tetrazolium-based detection, digital image analysis, and PCR-based marker detection from soft agar cultures.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
Purity & Documentation
References
[1]. Yamakoshi H, et al. Structure-activity relationship of C5-curcuminoids and synthesis of their molecular probes thereof. Bioorganic & medicinal chemistry. 2010 Feb;18(3):1083-92. [Content Brief]
[3]. Friedman L, et al. Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells. Anti-cancer drugs. 2009 Jul;20(6):444-9. [Content Brief]
[4]. Cen L, et al. New structural analogues of curcumin exhibit potent growth suppressive activity in human colorectal carcinoma cells. BMC cancer. 2009 Mar 30;9:99. [Content Brief]
[6]. Anisuzzaman AS, et al. Preclinical In Vitro, In Vivo, and Pharmacokinetic Evaluations of FLLL12 for the Prevention and Treatment of Head and Neck Cancers. Cancer prevention research (Philadelphia, Pa.). 2016 Jan;9(1):63-73. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)